Are Cindy Tahl’s Fate Therapeutics transactions open-market buys or compensation-related exercises?

The transactions are compensation-related option exercises, not open-market buys. Each is coded “M” for exercise or conversion of derivative security, indicating conversion of stock options into common shares under existing grants rather than discretionary market purchases.

Fate Therapeutics officer exercises 166,664 options

Fate Therapeutics officer Cindy Tahl exercised stock options to acquire a total of 166,664 shares of common stock on May 6, 2026.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Fate Therapeutics officer Cindy Tahl exercised stock options to acquire a total of 166,664 shares of common stock on May 6, 2026. She exercised 44,444 options at $1.05 per share and 122,220 options at $1.32 per share, with no open-market sales reported. Following these transactions, she directly holds 653,745 shares of common stock. The options exercised relate to grants that vest in 36 equal monthly installments starting January 1, 2025 and January 1, 2026, becoming fully vested in 2028 and 2029, subject to her continued service.

Insider Trade Summary

166,664 shares exercised/converted

Exercise 4 txns

Insider TAHL CINDY

Role See Remarks

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	122,220	$0.00	$0.00
Exercise	Stock Option (Right to Buy)	44,444	$0.00	$0.00
Exercise	Common Stock	122,220	$1.32	$161K
Exercise	Common Stock	44,444	$1.05	$47K

Holdings After Transaction: Stock Option (Right to Buy) — 508,336 contracts (Direct); Common Stock — 653,745 shares (Direct)

Footnotes (2)

F1. The shares subject to this option shall vest in 36 equal monthly installments following January 1, 2025, such that all of the shares shall be fully vested and exercisable on January 1, 2028, subject to the Reporting Person's continued service with the Issuer as of each such vesting date.
F2. The shares subject to this option shall vest in 36 equal monthly installments following January 1, 2026, such that all of the shares shall be fully vested and exercisable on January 1, 2029, subject to the Reporting Person's continued service with the Issuer as of each such vesting date.

Key Figures

Options exercised at $1.05: 44,444 shares at $1.05 Options exercised at $1.32: 122,220 shares at $1.32 Total shares acquired via exercise: 166,664 shares +3 more

6 metrics

Options exercised at $1.05 44,444 shares at $1.05 Stock option exercise into common stock on May 6, 2026

Options exercised at $1.32 122,220 shares at $1.32 Stock option exercise into common stock on May 6, 2026

Total shares acquired via exercise 166,664 shares Aggregate option exercises reported for May 6, 2026

Post-transaction common shares 609,301 shares Direct Fate Therapeutics common stock held after transactions

Option vesting period (F1 grant) 36 monthly installments Vests from January 1, 2025 to January 1, 2028

Option vesting period (F2 grant) 36 monthly installments Vests from January 1, 2026 to January 1, 2029

Key Terms

Stock Option (Right to Buy), Exercise or conversion of derivative security, vest in 36 equal monthly installments, fully vested and exercisable

4 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

Exercise or conversion of derivative security financial

"transaction_code_description: "Exercise or conversion of derivative security""

vest in 36 equal monthly installments financial

"The shares subject to this option shall vest in 36 equal monthly installments"

fully vested and exercisable financial

"such that all of the shares shall be fully vested and exercisable on January 1, 2028"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Cindy Tahl report in this Fate Therapeutics (FATE) Form 4?

Cindy Tahl exercised stock options to acquire Fate Therapeutics shares. On May 6, 2026, she converted options into 166,664 shares of common stock, with no open-market sales reported, increasing her direct equity stake in the company through routine compensation-related exercises.

How many Fate Therapeutics shares did Cindy Tahl acquire and at what prices?

She acquired 166,664 Fate Therapeutics common shares via option exercises. This included 44,444 shares at an exercise price of $1.05 per share and 122,220 shares at $1.32 per share, all recorded as derivative exercises rather than open-market purchases.

How many Fate Therapeutics shares does Cindy Tahl hold after these transactions?

After the exercises, Cindy Tahl directly holds 609,301 common shares. This figure reflects her post-transaction ownership reported in the Form 4, showing her ongoing equity position in Fate Therapeutics following the conversion of stock options into common stock.

Were any Fate Therapeutics shares sold by Cindy Tahl in this Form 4?

No sales were reported; only option exercises were disclosed. All transactions used code “M” for exercise or conversion of derivative securities, and transaction summaries show acquire-side activity without any open-market sales, gifts, or tax-withholding dispositions.

What do the Form 4 footnotes reveal about Cindy Tahl’s Fate Therapeutics options?

The footnotes describe the vesting schedules of her stock options. One grant vests in 36 equal monthly installments starting January 1, 2025, fully vesting January 1, 2028. Another vests similarly from January 1, 2026, fully vesting January 1, 2029, subject to continued service.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 05/07/2026 - 04:00 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

TAHL CINDY

(Last)

(First)

(Middle)

C/O FATE THERAPEUTICS, INC.

12278 SCRIPPS SUMMIT DRIVE

(Street)

SAN DIEGO

CALIFORNIA

92131

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
FATE THERAPEUTICS INC [ FATE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/06/2026		M		122,220	A	$1.32	609,301	D
Common Stock	05/06/2026		M		44,444	A	$1.05	653,745	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$1.32	05/06/2026		M			122,220	⁽¹⁾	01/14/2035	Common Stock	122,220	$0.00	152,780	D
Stock Option (Right to Buy)	$1.05	05/06/2026		M			44,444	⁽²⁾	01/14/2036	Common Stock	44,444	$0.00	355,556	D

Explanation of Responses:

1. The shares subject to this option shall vest in 36 equal monthly installments following January 1, 2025, such that all of the shares shall be fully vested and exercisable on January 1, 2028, subject to the Reporting Person's continued service with the Issuer as of each such vesting date.

2. The shares subject to this option shall vest in 36 equal monthly installments following January 1, 2026, such that all of the shares shall be fully vested and exercisable on January 1, 2029, subject to the Reporting Person's continued service with the Issuer as of each such vesting date.

Remarks:

Chief Legal and Compliance Officer

	/s/ Cindy Tahl	05/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR